Anlon Healthcare fixes ₹17.85 swap issue price in 2026

What the company disclosed and why it matters

Anlon Healthcare has finalised the pricing of its preferential allotment tied to a share-swap acquisition of Apiqo Organics and Bizotic Lifescience. The company set the issue price at ₹17.85 per equity share, a level it said matches an independent valuer’s fair value and aligns with SEBI ICDR requirements. The pricing matters because it sets the conversion value for shares issued as consideration rather than cash. It also frames the size of dilution, the promoter and public shareholding mix after allotment, and the timeline for completing the acquisition structure.

The disclosure follows shareholder approvals at the company’s 13th Annual General Meeting (AGM) held on September 5, 2026 via video conference. At that AGM, shareholders approved audited FY26 financial statements, director appointments, an increase in authorised share capital, and the preferential issue linked to acquisitions. The company later filed the voting results and the consolidated scrutinizer’s report with BSE and NSE.

Preferential issue structure approved at the AGM

The key resolution was a preferential issue of up to 8,58,83,617 fully paid-up equity shares as consideration other than cash for acquiring stakes in Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL). The equity shares carry a face value of ₹2 each. The issue price was set at ₹17.85 per share, including a security premium of ₹15.85.

In its AGM-related communications, Anlon Healthcare referred to the proposal as a ₹1,533 crore consideration transaction across the AOPL and BLPL components. The company also disclosed that the acquisition would be executed through a share swap mechanism, with Anlon Healthcare issuing its shares to the relevant parties in exchange for shares of AOPL and BLPL.

Stakes to be acquired through the share swap

Anlon Healthcare disclosed that the share swap is aimed at acquiring up to 44.94% stake in Apiqo Organics and up to 47.41% stake in Bizotic Lifescience. For AOPL, the company stated that 45,16,200 shares of AOPL are proposed to be swapped for 6,52,76,283 Anlon Healthcare shares priced at ₹17.85 per share. For BLPL, 22,99,000 shares are proposed to be swapped for 2,06,07,334 Anlon Healthcare shares priced at ₹17.85 per share.

The preferential allotment is split across the two components. The AOPL component involves the allotment of 6,52,76,283 shares to 159 proposed allottees. The BLPL component includes the allotment of 2,06,07,334 shares to 171 proposed allottees. These are the numbers the company outlined in its AGM-related documents and follow-on filings.

AGM corrigendum and exchange observations

On August 25, 2026, Anlon Healthcare issued a corrigendum to its AGM notice. The corrigendum addressed observations from BSE and NSE regarding the proposed preferential share issue. In that corrigendum, the company also stated that the issue price of ₹17.85 was aligned with NSE’s volume-weighted average price of ₹17.78.

The corrigendum described the preferential issue as having two components and provided component-level values: ₹1,165,179,600 for the AOPL component and ₹367,840,000 for the BLPL component. Based on those figures, the component values work out to about ₹116.52 crore and ₹36.78 crore respectively. Separately, the company also referred to the broader transaction as a ₹1,533 crore consideration item in AGM communications, and both sets of figures were part of the disclosed information.

Promoter participation and expected shareholding changes

Anlon Healthcare disclosed that only two promoters indicated an intention to subscribe to the offer. These were:

• Punitkumar Rameshbhai Rasadia (Promoter and Chairman and Managing Director): 1,84,19,402 shares
• Meet Atulkumar Vachhani (Promoter and Whole Time Director): 93,51,099 shares

The company also identified the largest single allottee in the AOPL component as Punitkumar Rameshbhai Rasadia, proposed to receive 1,75,23,043 shares valued at ₹312,786,300 (about ₹31.28 crore based on the disclosed number).

Post-issue, the promoter group’s shareholding is expected to decline from 52.68% to 49.85%. Public shareholding is expected to rise from 47.32% to 50.15%, which the company linked to maintaining minimum public shareholding norms.

Capital structure: authorised share capital and equity base

Shareholders also approved an enhancement of authorised share capital from ₹110 crore to ₹130 crore. The company disclosed that, after the preferential issue, the total number of equity shares is expected to increase from 53,15,15,000 to 61,73,98,617.

This combination of authorised capital increase and expansion in equity base provides the legal headroom for issuing the preferential shares and completing the share-swap consideration structure as approved.

Board meeting on October 13, 2026: expansion and fundraising agenda

Anlon Healthcare informed BSE that a Board of Directors meeting is scheduled for October 13, 2026. The agenda includes discussions on business expansion plans in India and or overseas, and raising of funds or financing for those plans. The company indicated the board may consider one or more tranches through permissible modes, including equity, debt, hybrid instruments, borrowings, or a combination, subject to regulatory and other approvals.

This disclosure places the preferential issue and acquisition-related approvals alongside a broader financing and expansion agenda that the board plans to deliberate on.

Key facts at a glance

Market impact and what investors can track

The most direct market-relevant datapoint in the disclosures is the preferential issue price of ₹17.85 and the scale of the issuance at up to 8,58,83,617 shares. The company also highlighted alignment with an NSE volume-weighted average price of ₹17.78, which provides a reference point for how the issue price compares with recent trading data mentioned in the corrigendum.

Investors can also track the post-issue ownership mix disclosed by the company, where public shareholding is expected to move above 50%. Separately, the October 13, 2026 board meeting agenda is relevant because it explicitly includes fundraising options across equity, debt, hybrid instruments, and borrowings. Any subsequent board decision and regulatory filings would add clarity on financing route, sizing, and timelines.

Conclusion

Anlon Healthcare has locked in ₹17.85 as the preferential issue price for its share-swap acquisition of Apiqo Organics and Bizotic Lifescience, after shareholder approvals at the September 5, 2026 AGM. The company has also secured approval to increase authorised share capital to ₹130 crore and disclosed expected changes in shareholding and the expanded equity base. The next near-term trigger is the board meeting scheduled for October 13, 2026, where the company plans to deliberate on expansion plans and potential fundraising modes, subject to approvals and further disclosures.